Development of a peptide-drug conjugate for prostate cancer therapy. - Wikidata - wikimedia - TriplyDB

Development of a peptide-drug conjugate for prostate cancer therapy.

Development of a peptide-drug conjugate for prostate cancer therapy.

http://www.wikidata.org/entity/Q35184864

about

Prostate cancer relevant antigens and enzymes for targeted drug delivery Targeted nanodiamonds as phenotype-specific photoacoustic contrast agents for breast cancer.In vivo photoacoustic imaging of breast cancer tumor with HER2-targeted nanodiamonds Folding graft copolymer with pendant drug segments for co-delivery of anticancer drugs Expression profile and functional activity of peptide transporters in prostate cancer cells.Advancement and applications of peptide phage display technology in biomedical science Design, synthesis, and evaluation of cisplatin-containing EGFR targeting bioconjugates as potential therapeutic agents for brain tumors Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors.A novel rapamycin-polymer conjugate based on a new poly(ethylene glycol) multiblock copolymer.Targeted drug delivery for cancer therapy: the other side of antibodies.Chemical modulation of bioactive compounds via oligopeptide or amino acid conjugation.Targeting kallikrein-related peptidases in prostate cancer.PI-3 kinase p110β: a therapeutic target in advanced prostate cancers.Kallikrein-related peptidases targeted therapies in prostate cancer: perspectives and challenges.Characterization of a novel p110β-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells.Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.Prodrug strategy for PSMA-targeted delivery of TGX-221 to prostate cancer cells.Targeting PEPT1: a novel strategy to improve the antitumor efficacy of doxorubicin in human hepatocellular carcinoma therapy Specific expression of proton-coupled oligopeptide transporter 1 in primary hepatocarcinoma-a novel strategy for tumor-targeted therapy.Bio-inspired synthetic nanovesicles for glucose-responsive release of insulin.Anticancer activities of emetine prodrugs that are proteolytically activated by the prostate specific antigen (PSA) and evaluation of in vivo toxicity of emetine derivatives.Potent inhibitors of phosphatidylinositol 3 (PI3) kinase that have antiproliferative activity only when delivered as prodrug forms.

P2860

Q27013843-EB552070-2545-4005-86C1-C3DEF1D420F0 Q30389883-13A95E31-90E5-4268-BF4E-0CF7E673B6AA Q30420459-B964D6D1-7F2D-44DB-824A-47437A33AA2C Q33936160-BD00DD01-1F4C-4968-B44D-FC0426D9F680 Q34267875-A79D6710-1320-4683-AC24-6DF9695CEBA2 Q35898339-B985E0AD-BBAC-488E-96CE-C2E9D7A2B15C Q36907976-681B2E94-36CB-41EA-97C3-282957D0E0D9 Q37011768-41861E51-C0F4-4CC5-9361-F406408FF078 Q37698614-D6BE7D56-DB56-4BD1-A1D6-7AAA463A069E Q38058816-D1344178-3D40-4022-97C8-6F05476A2EE2 Q38124818-4DDC2BDF-92C4-4DDF-8F86-FF715BF2CD5E Q38191293-368DDCBE-C5B5-489E-A4D1-9C985E7EBAFD Q38265574-0876A182-AC15-4872-BBA5-DDF24FA20DF2 Q38413737-F885A91A-CDFE-4313-ABFD-3B0430B38B24 Q38699761-BCEEE8DA-3660-4F15-A540-CAD67B148A1D Q38760061-D5AD2385-53A1-4B70-9907-44B28946CF5C Q39365953-E6EF099A-9BC0-4446-BCD5-D672B497CAB5 Q41093055-8FF96B93-C5D0-4890-AF48-653E5D7554C1 Q41388290-4450245C-6D59-4B3B-96AE-F71DDBF8C0CA Q41974259-E3C754D1-EE65-4B9A-ACCA-5BC16A98E926 Q47387421-636A29DD-5AC7-4BDD-89AD-41D5962C79AC Q54438686-5108FDE6-0464-42A3-B178-A228D875B65D

P2860

Development of a peptide-drug conjugate for prostate cancer therapy.

http://www.wikidata.org/entity/Q35184864

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Development of a peptide-drug conjugate for prostate cancer therapy.

@ast

Development of a peptide-drug conjugate for prostate cancer therapy.

@en

type

label

Development of a peptide-drug conjugate for prostate cancer therapy.

@ast

Development of a peptide-drug conjugate for prostate cancer therapy.

@en

prefLabel

Development of a peptide-drug conjugate for prostate cancer therapy.

@ast

Development of a peptide-drug conjugate for prostate cancer therapy.

@en

P1433

Q35184864-27B580CE-BBB7-4C26-8E29-8E1FB3BA27C1

P1476

Q35184864-A716CB00-9621-4882-8583-954BB831C687

P2093

Q35184864-06DD77CA-5253-4315-8254-FD9AA41CD13A

Q35184864-8A729DA4-BFC8-4C3E-8FF6-1C87FD0577EF

Q35184864-DA9C71C9-8057-4749-A68E-AEEA1F4BF2D6

Q35184864-DF36404D-11BA-460F-8D2C-9870C9BE7F44

P2860

Q35184864-0649899D-E137-4F5D-979A-E44B3E89162E

Q35184864-087A083A-FF4D-42DC-89AE-5D7BBCECCBE1

Q35184864-0CA0DA85-041E-4147-AC73-BA66797B2AD7

Q35184864-144FA7B8-D289-4CF6-84CA-446F508DFDC7

Q35184864-1490BE96-71B8-4BEE-9796-A69E9C83C8B1

Q35184864-172FAB63-14B2-47FD-BDB6-7BF8BF883C0C

Q35184864-18905C6E-9567-42D8-A92B-7F05CE158D58

Q35184864-207ED779-0C48-4A0C-BCF1-27B699E904FD

Q35184864-2755A675-75BE-4F92-BEDD-88100001FEBD

Q35184864-3022CD13-82FE-4893-84C6-CB92D51EC629

P304

Q35184864-48BA090E-D771-43BF-AB58-C88207C9739E

P31

Q35184864-C16897D9-7D8B-4AA9-A6B2-F206B0B3C8A5

P356

Q35184864-7A46DFBD-2097-4BFF-9728-2FCAB8407C89

P407

Q35184864-1EF1C135-781B-44A3-81E5-B90AFD632B08

P433

Q35184864-02418F9C-E386-43E9-BEA1-2FCBB61D493C

P478

Q35184864-48C3A5C5-33D9-4144-8CB5-CA1D763C6557

P50

Q35184864-C4EBD153-6FA3-4818-A08C-A90DE19CDED7

P577

Q35184864-9D638ED7-827D-4B47-A52C-402E75CEF22F

P5875

Q35184864-334354C8-48A7-4F9A-868A-22B158B567B3

P698

Q35184864-F8C93EF5-5A0B-4B28-8842-2305D864E2C6

P932

Q35184864-67AF87D5-5780-48F8-BCC0-6B4C546195A1

P356

P1433

Molecular Pharmaceutics

P1476

Development of a peptide-drug conjugate for prostate cancer therapy

@en

P2093

Benyi Li

http://www.w3.org/2001/XMLSchema#string

Bin Qin

http://www.w3.org/2001/XMLSchema#string

Kun Cheng

http://www.w3.org/2001/XMLSchema#string

Ravi S Shukla

http://www.w3.org/2001/XMLSchema#string

P2860

FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

Targeting phosphoinositide 3-kinase: moving towards therapy

PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer

Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers

Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase

PI 3-kinase p110beta: a new target for antithrombotic therapy

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

Identification and characterization of peptides that bind human ErbB-2 selected from a bacteriophage display library.

The role of HER2 in cancer therapy and targeted drug delivery

P304

901-912

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/MP200007B

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-05-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51068007

http://www.w3.org/2001/XMLSchema#string

P698

21510670

http://www.w3.org/2001/XMLSchema#string

P932

3163154

http://www.w3.org/2001/XMLSchema#string